The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle atrophy (SMA) progression and could be applied to other motoneuron diseases, ...

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, ...

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.

ZURICH and NESS ZIONA, Israel - NLS Pharmaceutics Ltd. (Nasdaq: NLSP) and Kadimastem Ltd. (TASE: KDST) announced plans for a merger, aiming to enhance diabetes treatment by combining their expertise ...

Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.

Sometimes the love stories in romantic dramas are fanciful and hard to believe, but these love stories were inspired by ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...

The ALS community identified three critical priority areas for the year ahead: expanding research and clinical trial access, enhancing financial support systems, and improving healthcare access ...